Alnylam Pharmaceuticals Inc’s filing revealed that its CMO & EVP Dev & Med Affairs Garg Pushkal unloaded Company’s shares for reported $0.44 million on Dec 12 ’24. In the deal valued at $251.00 per share,1,752 shares were sold. As a result of this transaction, Garg Pushkal now holds 15,705 shares worth roughly $3.66 million.
Then, Garg Pushkal bought 1,752 shares, generating $446,795 in total proceeds.
Before that, Greenstreet Yvonne sold 5,219 shares. Alnylam Pharmaceuticals Inc shares valued at $1,309,853 were divested by the Chief Executive Officer at a price of $250.98 per share. As a result of the transaction, Greenstreet Yvonne now holds 78,880 shares, worth roughly $18.39 million.
Wolfe Research downgraded its Alnylam Pharmaceuticals Inc [ALNY] rating to an Underperform from a a Peer perform in a research note published recently. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in mid October with a ‘”a Sector outperform”‘ rating. Goldman also remained covering ALNY and has increased its forecast on August 16, 2024 with a “Buy” recommendation from previously “Neutral” rating. Goldman revised its rating on February 16, 2024. It rated ALNY as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ALNY
On Monday, Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] saw its stock fall -0.48% to $233.15. Over the last five days, the stock has lost -2.03%. Alnylam Pharmaceuticals Inc shares have fallen nearly -0.92% since the year began. Nevertheless, the stocks have risen 21.24% over the past one year. While a 52-week high of $304.39 was reached on 01/02/25, a 52-week low of $141.98 was recorded on 01/06/25. SMA at 50 days reached $254.57, while 200 days put it at $225.21.
Levels Of Support And Resistance For ALNY Stock
The 24-hour chart illustrates a support level at 230.27, which if violated will result in even more drops to 227.39. On the upside, there is a resistance level at 236.76. A further resistance level may holdings at 240.37. The Relative Strength Index (RSI) on the 14-day chart is 33.96, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -5.68, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 88.43%. Stochastics %K at 9.73% indicates the stock is a buying.
How much short interest is there in Alnylam Pharmaceuticals Inc?
A steep rise in short interest was recorded in Alnylam Pharmaceuticals Inc stocks on 2024-12-13, dropping by -0.25 million shares to a total of 3.49 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 3.74 million shares. There was a decline of -7.18%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on February 15, 2024 when Wolfe Research began covering the stock and recommended ‘”a Peer perform”‘ rating .
